aibio.space IPO Desk
Biotech, medtech and pharma IPOs: pricings, upsizes, closings, S-1 and F-1 filings, lock-ups and early trading.
Sources: SEC filings and company press releases, with wires, trade press and court dockets used as leads and confirmed against a filing. The desk follows our editorial standards. 79 stories so far.
Latest stories
- Curanex discloses two New York class actions tied to its August 2025 IPO
- City Therapeutics raises $200 million in upsized IPO priced at $18
- Iambic Therapeutics prices IPO of 9,375,000 shares at $16.00
- Retension Pharmaceuticals prices IPO of 3,750,000 shares at $12.00
- TRex Bio prices IPO of 8,333,334 shares at $14.00 each
- ADARx Pharmaceuticals closes IPO of 26,250,000 shares at $17.00 each
- Iambic Therapeutics files for IPO, plans Nasdaq listing as IAM
- Electra Therapeutics prices IPO of 23,333,334 shares at $15.00, about $350 million
- Retension Pharmaceuticals files for IPO, seeks Nasdaq listing as RTSN
- TRex Bio files for IPO as Eli Lilly signals interest in buying shares
- ADARx Pharmaceuticals files for IPO, plans Nasdaq listing as ADRX
- Electra Therapeutics files for IPO, plans Nasdaq listing as ETRA
- Neumora IPO class action over navacaprant disclosures awaits ruling on dismissal motion
- Alto Neuroscience IPO securities class action dismissed with leave to amend
- Vogenx prices IPO of 6,250,000 shares at $13.00 on Nasdaq
- Kyverna faces IPO securities class action and consolidated derivative suit
- Metagenomi's IPO class action over Moderna collaboration disclosures moves into discovery
- BlossomHill prices IPO of 9,375,000 shares at $16.00, $150,000,000 in total
- Latigo Biotherapeutics prices IPO of 19,200,000 shares at $18.00
- AgomAb Therapeutics NV reports €252.0 million cash after $208 million IPO
- Braveheart Bio prices IPO of 21,250,000 shares at $18.00
- BioAge faces Ninth Circuit appeal of dismissed IPO securities class action
- Attovia Therapeutics prices IPO of 17,000,000 shares at $17.00
- Apnimed prices IPO of 12,000,000 shares at $16.00
- Scribe Therapeutics prices IPO of 8,580,000 shares at $15.00
- BlossomHill Therapeutics files for IPO, plans Nasdaq listing as BLSM
- Latigo Biotherapeutics files for IPO, plans Nasdaq listing as LTGO
- Braveheart Bio files for IPO, plans Nasdaq Global Market listing as BRVE
- Vogenx files for IPO, plans Nasdaq Capital Market listing as VOGX
- Attovia Therapeutics files for IPO, plans Nasdaq listing as ATTO
- Apnimed files for IPO, plans Nasdaq Global Market listing as APMD
- Scribe Therapeutics files for IPO, plans Nasdaq listing as SCTX
- Kardigan prices IPO of 25,000,000 shares at $16.00
- Parabilis Medicines closes private placement of 4,166,666 shares to Regeneron alongside IPO
- Parabilis Medicines prices IPO of 33,500,000 shares at $20.00, $670,000,000 in total
- Kardigan files for IPO, plans Nasdaq Global Market listing as KARD
- Optimi Health prices US IPO of 2,400,000 shares at US$6.25
- Parabilis Medicines files for IPO; Regeneron agrees to buy about $75.0 million of stock
- Hemab Therapeutics Holdings prices $301,500,000 IPO at $18.00 per share
- Seaport Therapeutics prices IPO of 14,160,000 shares at $18.00
aibio